Overview

* Humana Q3 adjusted EPS of $3.24 beats analyst expectations

* Q3 adjusted revenue of $32.65 bln exceeds analyst estimates

* Company updates FY 2025 GAAP EPS guidance to $12.26 from $13.77

Outlook

* Humana affirms FY 2025 adjusted EPS guidance of approximately $17.00

* Humana revises FY 2025 GAAP EPS guidance to approximately $12.26

* Humana anticipates FY 2025 Medicare Advantage membership decline of 425,000

Result Drivers

* MEDICARE ADVANTAGE MEMBERSHIP - Decline less severe than anticipated, attributed to stronger retention and better-than-expected sales

* CENTERWELL GROWTH - Nearly 15% growth in CenterWell Primary Care patients compared to December 31, 2024

* DUAL ELIGIBLE PROGRAMS - Preparing for launch of new dual eligible programs in Michigan, Illinois, and South Carolina

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $32.65 $32.01

Adjusted bln bln (18

Revenue Analysts

)

Q3 Beat $3.24 $2.81

Adjusted (25

EPS Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 8 "strong buy" or "buy", 20 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the managed healthcare peer group is "buy."

* Wall Street's median 12-month price target for Humana Inc ( HUM ) is $295.00, about 4.5% above its November 4 closing price of $281.87

* The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 17 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)